| | 54350-48-0 Basic information More.. |
| Product Name: | Etretinate | | Synonyms: | 2,4,6,8-nonanetetraenoicacid,9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl;3,7-dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonanetetraenoicaci;all-trans-ethylester;(2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonanetetraenoic acid ethyl ester;(2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid ethyl;(2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid ethyl ester;Acitretin Related Compound B (20 mg) (ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate);Acitretin Related CoMpound B | | CAS: | 54350-48-0 | | MF: | C23H30O3 | | MW: | 354.48 | | EINECS: | 259-119-3 | | Mol File: | 54350-48-0.mol |  |
Use
Etretinate, a retinol derivative, was introduced in 1981 for the
treatment of psoriasis. Its use in pregnant women has resulted in major foetal
abnormalities. The manufacturer's information emphasizes that the drug is
teratogenic and must not be given to women who are pregnant, and that
contraceptive measures must be maintained for at least two years after
discontinuation of treatment. In some countries, blood banks are advised not to
accept as donors persons who have taken etretinate within the previous year.
- Etretinate
-
- $50.00
- 2026-05-25
- CAS:54350-48-0
- Purity: 99.48%
- Supply Ability: 10g
- Etretinate
-
- $1.10
- 2025-06-25
- CAS:54350-48-0
- Min. Order: 1g
- Purity: 99.0% min
- Supply Ability: 100 tons min
- Etretinate
-
- $1.00
- 2020-02-05
- CAS:54350-48-0
- Min. Order: 1KG
- Purity: 98%-99.9%HPLC
- Supply Ability: 100KG
|
|
54350-48-0
Recommend
Suppliers |
|
|
Recommend You Select Member Companies |
|
|